10 August 2005
Late onset renal failure from angiotensin blockade (LORFFAB): a prospective thirty-month Mayo Health System clinic experienceMacaulay A C Onuigbo, Nnonyelum T C Onuigbo
Med Sci Monit 2005; 11(10): CR462-469 :: ID: 430303
BACKGROUND: Worsening azotemia following initiation of angiotensin blockade(AB), in patients with CKD, RAS with/without precipitating factors is recognized. Small increases inserum creatinine following initiation of AB occur and must not warrant drug discontinuation. We anecdotallyhad observed improvement in CKD in patients with normal renal arteries and no precipitating factors,following termination of AB. The worldwide ESRD epidemic, coincident with increasing use of AB, promptedus to hypothesize a late-onset azotemia in such CKD patients. MATERIAL/METHODS: Over 30 months, 103 patientswith worsening azotemia, while on AB were evaluated. Ninety-seven patients with abnormal MRA and/or withprecipitating factors were excluded. In the remaining five, AB was discontinued, and GFR monitored. RESULTS:One male, four females, mean age 66.2 years. Three diabetic/hypertensives, one SLE/hypertensive, onediabetic/kidney transplant recipient. Mean stable AB, 25.2 months, (6-66 months). Mean follow up, 11.8months. One month following discontinuation of AB, GFR increased by a mean 45%. Mean serum creatininedecreased from 2.9+/-0.9 to 1.8+/-0.4 mg/dL (p=0.04). Uremic symptoms in 3, hyperkalemia in one, secondaryhyperparathyroidism in one, resolved. Two with anemia, now require less erythropoietin. CONCLUSIONS:We called this unrecognized potentially reversible late-onset worsening azotemia, occurring several monthsto years on stable AB, in CKD patients with normal renal arteries, without precipitating factors, late-onsetrenal failure from angiotensin blockade (LORFFAB). Pathophysiologically, the concept of microvascularRAS is invoked. The extent of LORFFAB, with millions of patients worldwide on AB, remains conjecturaland warrants further investigation.
Keywords: Angiotensin II Type 1 Receptor Blockers - adverse effects, Aged, 80 and over, angiotensin receptor antagonists, Angiotensin-Converting Enzyme Inhibitors - adverse effects, Blood Pressure, Creatinine - urine, Glomerular Filtration Rate, Kidney Failure, Chronic - urine, Prospective Studies, Uremia - physiopathology, Wisconsin
04 June 2022 : EditorialEditorial: Acute Hepatitis of Unknown Origin in Children. Is Autoimmunity at Play?
Med Sci Monit 2022; 28:e937371
27 Jun 2022 : Clinical ResearchAutomatic Identification of Depression Using Facial Images with Deep Convolutional Neural Network
Med Sci Monit In Press; DOI: 10.12659/MSM.936409
23 Jun 2022 : Clinical ResearchA Real-World Study to Compare the Safety and Efficacy of Paritaprevir/Ombitasvir/Ritonavir and Dasabuvir, w...
Med Sci Monit In Press; DOI: 10.12659/MSM.936706
22 Jun 2022 : Clinical ResearchA Single-Center Study Comparing the Effects of Thoracic Spine Manipulation vs Mobility Exercises in 26 Offi...
Med Sci Monit In Press; DOI: 10.12659/MSM.937316
Most Viewed Current Articles
30 Dec 2021 : Clinical ResearchRetrospective Study of Outcomes and Hospitalization Rates of Patients in Italy with a Confirmed Diagnosis o...
Med Sci Monit 2021; 27:e935379
08 Mar 2022 : Review articleA Review of the Potential Roles of Antioxidant and Anti-Inflammatory Pharmacological Approaches for the Man...
Med Sci Monit 2022; 28:e936292
01 Nov 2020 : Review articleLong-Term Respiratory and Neurological Sequelae of COVID-19
Med Sci Monit 2020; 26:e928996